Clinical trial

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

NCT00769223

Study summary

ClinicalTrials.gov

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Design: OBSERVATIONAL · Status: ACTIVE NOT RECRUITING · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention medical chart review Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention questionnaire administration Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention quality-of-life assessment Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention brachytherapy Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention radiation therapy Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date1993-02-25

PhaseN/A

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Radiation Toxicityunresolved

Interventions

medical chart reviewOTHER

questionnaire administrationOTHER

quality-of-life assessmentPROCEDURE

brachytherapyRADIATION

radiation therapyRADIATION

Sponsors & collaborators

University of California, San Franciscolead sponsor

Mapped research locations

San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00769223 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.